BioNTech SE (BNTX)

BioNTech SE Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
4 Buy
6 Hold
0 Sell
Based on 10 analysts giving stock ratings to
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BNTX Stock Price Prediction

Average Price Target

▲(58.67% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $211.00 with a high forecast of $312.00 and a low forecast of $168.00. The average price target represents a 58.67% change from the last price of $132.98.
Highest Price Target$312.00Average Price Target$211.00Lowest Price Target$168.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and Relay Therapeutics (NASDAQ: RLAY)
Bank of America Securities
BioNTech (BNTX) PT Lowered to $254 at BofA SecuritiesBofA Securities analyst Tazeen Ahmad lowered the price target on BioNTech (NASDAQ: BNTX) to $254.00 (from $255.00) while maintaining a Neutral rating.
Redburn Partners
BioNTech upgraded to Neutral from Sell at RedburnBioNTech upgraded to Neutral from Sell at Redburn
Kempen & Co
BioNTech upgraded to Buy from Neutral at KempenBioNTech upgraded to Buy from Neutral at Kempen
Bryan Garnier & Co Ltd
Bryan Garnier & Co Ltd Stick to Their Buy Rating for BioNTech SEBryan Garnier & Co Ltd analyst Olga Smolentseva maintained a Buy rating on BioNTech SE on Monday, setting a price target of $359, which is approximately 43.53% above the present share price of $250.12.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is $211.00.
    What is BNTX’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 58.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BNTX a Buy, Sell or Hold?
          BioNTech SE has a conensus rating of Moderate Buy which is based on 4 buy ratings, 6 hold ratings and 0 sell ratings.
            What is BioNTech SE’s price target?
            The average price target for BioNTech SE is $211.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $312.00 ,the lowest forecast is $168.00. The average price target represents 58.67% Increase from the current price of $132.98.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis